Literature DB >> 20685848

Structure-activity relationships of GPR120 agonists based on a docking simulation.

Qi Sun1, Akira Hirasawa, Takafumi Hara, Ikuo Kimura, Tetsuya Adachi, Takeo Awaji, Masaji Ishiguro, Takayoshi Suzuki, Naoki Miyata, Gozoh Tsujimoto.   

Abstract

GPR120 is a G protein-coupled receptor expressed preferentially in the intestinal tract and adipose tissue, that has been implicated in mediating free fatty acid-stimulated glucagon-like peptide-1 (GLP-1) secretion. To develop GPR120-specific agonists, a series of compounds (denoted as NCG compounds) derived from a peroxisome proliferator-activated receptor γ agonist were synthesized, and their structure-activity relationships as GPR120 agonists were explored. To examine the agonistic activities of these newly synthesized NCG compounds, and of compounds already shown to have GPR120 agonistic activity (grifolic acid and MEDICA16), we conducted docking simulation in a GPR120 homology model that was developed on the basis of a photoactivated model derived from the crystal structure of bovine rhodopsin. We calculated the hydrogen bonding energies between the compounds and the GPR120 model. These energies correlated well with the GPR120 agonistic activity of the compounds (R(2) = 0.73). NCG21, the NCG compound with the lowest calculated hydrogen bonding energy, showed the most potent extracellular signal-regulated kinase (ERK) activation in a cloned GPR120 system. Furthermore, NCG21 potently activated ERK, intracellular calcium responses and GLP-1 secretion in murine enteroendocrine STC-1 cells that express GPR120 endogenously. Moreover, administration of NCG21 into the mouse colon caused an increase in plasma GLP-1 levels. Taken together, our present study showed that a docking simulation using a GPR120 homology model might be useful to predict the agonistic activity of compounds.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685848     DOI: 10.1124/mol.110.066324

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  30 in total

1.  FFA1-selective agonistic activity based on docking simulation using FFA1 and GPR120 homology models.

Authors:  Masato Takeuchi; Akira Hirasawa; Takafumi Hara; Ikuo Kimura; Tatsuya Hirano; Takayoshi Suzuki; Naoki Miyata; Takeo Awaji; Masaji Ishiguro; Gozoh Tsujimoto
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

Review 2.  Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4.

Authors:  G Milligan; E Alvarez-Curto; K R Watterson; T Ulven; B D Hudson
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

3.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 4.  The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.

Authors:  Charles N Serhan; Nan Chiang; Jesmond Dalli
Journal:  Semin Immunol       Date:  2015-04-07       Impact factor: 11.130

5.  Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human.

Authors:  Atsuhiko Ichimura; Akira Hirasawa; Odile Poulain-Godefroy; Amélie Bonnefond; Takafumi Hara; Loïc Yengo; Ikuo Kimura; Audrey Leloire; Ning Liu; Keiko Iida; Hélène Choquet; Philippe Besnard; Cécile Lecoeur; Sidonie Vivequin; Kumiko Ayukawa; Masato Takeuchi; Kentaro Ozawa; Maithé Tauber; Claudio Maffeis; Anita Morandi; Raffaella Buzzetti; Paul Elliott; Anneli Pouta; Marjo-Riitta Jarvelin; Antje Körner; Wieland Kiess; Marie Pigeyre; Roberto Caiazzo; Wim Van Hul; Luc Van Gaal; Fritz Horber; Beverley Balkau; Claire Lévy-Marchal; Konstantinos Rouskas; Anastasia Kouvatsi; Johannes Hebebrand; Anke Hinney; Andre Scherag; François Pattou; David Meyre; Taka-aki Koshimizu; Isabelle Wolowczuk; Gozoh Tsujimoto; Philippe Froguel
Journal:  Nature       Date:  2012-02-19       Impact factor: 49.962

6.  Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes.

Authors:  Xuqing Zhang; Chaozhong Cai; Zhihua Sui; Mark Macielag; Yuanping Wang; Wen Yan; Arthur Suckow; Hong Hua; Austin Bell; Peter Haug; Wilma Clapper; Celia Jenkinson; Joseph Gunnet; James Leonard; William V Murray
Journal:  ACS Med Chem Lett       Date:  2017-07-27       Impact factor: 4.345

Review 7.  Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases.

Authors:  Saswata Talukdar; Jerrold M Olefsky; Olivia Osborn
Journal:  Trends Pharmacol Sci       Date:  2011-06-12       Impact factor: 14.819

8.  Pharmacological characterization of the cytoprotective effects of polyunsaturated fatty acids in insulin-secreting BRIN-BD11 cells.

Authors:  Shalinee Dhayal; Noel G Morgan
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

9.  Omega-3 fatty acids and other FFA4 agonists inhibit growth factor signaling in human prostate cancer cells.

Authors:  Ze Liu; Mandi M Hopkins; Zhihong Zhang; Chrystal B Quisenberry; Louise C Fix; Brianna M Galvan; Kathryn E Meier
Journal:  J Pharmacol Exp Ther       Date:  2014-12-09       Impact factor: 4.030

Review 10.  G protein-coupled receptors for energy metabolites as new therapeutic targets.

Authors:  Clara C Blad; Cong Tang; Stefan Offermanns
Journal:  Nat Rev Drug Discov       Date:  2012-07-13       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.